Literature DB >> 8017446

Non-Candida fungal infections after bone marrow transplantation: risk factors and outcome.

V A Morrison1, R J Haake, D J Weisdorf.   

Abstract

PURPOSE: To determine the incidence, risk factors, and outcome of non-Candida fungal infections in a bone marrow transplant population. PATIENTS AND METHODS: A consecutive series of 1,186 patients who underwent bone marrow transplant at the University of Minnesota Hospital between 1974 and 1989 were analyzed for the occurrence of a post-transplant non-Candida fungal infection. The risk factors were analyzed with regard to clinical characteristics such as age, sex, primary disease process, type of transplant, recipient cytomegalovirus serostatus, time to engraftment, and the presence of graft-versus-host disease.
RESULTS: In this population, 123 of 1,186 patients (10%) developed a non-Candida fungal infection within 180 days of transplant. The majority of infections (85%) occurred in allogeneic recipients, and 58% of infections were prior to white blood cell engraftment. The most common isolates were Aspergillus species (70%), Fusarium species (8%), and Alternaria species (5%). Although 47% of infections involved a single organ or site, 44% were disseminated and 9% were isolated fungemias. Only 17% of patients survived. Sixty-eight percent of deaths were related to the fungal infection. In univariate analysis, allogeneic transplant, positive recipient cytomegalovirus serostatus, delayed engraftment, and recipient age of greater than or equal to 18 years were identified as risk factors for non-Candida fungal infection. All of these factors except for recipient age were independently significant in multivariate analysis. In allogeneic recipients, positive cytomegalovirus serostatus, delayed engraftment, and age of greater than or equal to 18 years were each significantly associated with a greater risk of fungal infection; none of these factors were independently significant in the autologous recipients.
CONCLUSION: Fungal infections remain a major cause of morbidity and mortality in patients undergoing bone marrow transplant. More effective antifungal prophylaxis and therapy, earlier diagnosis, and transplant regimens incurring a brief period of neutropenia may substantially reduce the incidence and clinical impact of these infections.

Entities:  

Mesh:

Year:  1994        PMID: 8017446     DOI: 10.1016/0002-9343(94)90088-4

Source DB:  PubMed          Journal:  Am J Med        ISSN: 0002-9343            Impact factor:   4.965


  28 in total

1.  In vitro activity of Syn-2869, a novel triazole agent, against emerging and less common mold pathogens.

Authors:  E M Johnson; A Szekely; D W Warnock
Journal:  Antimicrob Agents Chemother       Date:  1999-05       Impact factor: 5.191

2.  Aspergillus antigen testing in bone marrow transplant recipients.

Authors:  E C Williamson; D A Oliver; E M Johnson; A B Foot; D I Marks; D W Warnock
Journal:  J Clin Pathol       Date:  2000-05       Impact factor: 3.411

Review 3.  Antifungal prophylaxis during neutropenia and immunodeficiency.

Authors:  O Lortholary; B Dupont
Journal:  Clin Microbiol Rev       Date:  1997-07       Impact factor: 26.132

4.  Comparison of in vitro activity of liposomal nystatin against Aspergillus species with those of nystatin, amphotericin B (AB) deoxycholate, AB colloidal dispersion, liposomal AB, AB lipid complex, and itraconazole.

Authors:  K L Oakley; C B Moore; D W Denning
Journal:  Antimicrob Agents Chemother       Date:  1999-05       Impact factor: 5.191

5.  In vitro activity of the new triazole BMS-207147 against Aspergillus species in comparison with itraconazole and amphotericin B.

Authors:  C B Moore; C M Walls; D W Denning
Journal:  Antimicrob Agents Chemother       Date:  2000-02       Impact factor: 5.191

Review 6.  Aspergillus infections in transplant recipients.

Authors:  Nina Singh; David L Paterson
Journal:  Clin Microbiol Rev       Date:  2005-01       Impact factor: 26.132

7.  Caspofungin and liposomal amphotericin B therapy of experimental murine scedosporiosis.

Authors:  Rosie Bocanegra; Laura K Najvar; Steve Hernandez; Dora I McCarthy; John R Graybill
Journal:  Antimicrob Agents Chemother       Date:  2005-12       Impact factor: 5.191

Review 8.  Key issues concerning fungistatic versus fungicidal drugs.

Authors:  J R Graybill; D S Burgess; T C Hardin
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1997-01       Impact factor: 3.267

9.  Development of a LightCycler PCR assay for detection and quantification of Aspergillus fumigatus DNA in clinical samples from neutropenic patients.

Authors:  Birgit Spiess; Dieter Buchheidt; Corinna Baust; Heyko Skladny; Wolfgang Seifarth; Udo Zeilfelder; Christine Leib-Mösch; Handan Mörz; Rüdiger Hehlmann
Journal:  J Clin Microbiol       Date:  2003-05       Impact factor: 5.948

Review 10.  Primary invasive aspergillosis of the digestive tract: report of two cases and review of the literature.

Authors:  P Eggimann; J-C Chevrolet; M Starobinski; P Majno; M Totsch; B Chapuis; D Pittet
Journal:  Infection       Date:  2006-12       Impact factor: 3.553

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.